Pfizer Inc 8-K, filed Mar 2, 2020
Pfizer Inc (PFE)
8-K
2020-03-02
For: 2020-02-27
View Original
Added on
April 10, 2026
About this 8-K
Pfizer Inc filed this 8-K on March 2, 2020, reporting on events of February 27, 2020.
Items reported
- Item 5.02: Director or officer change, or executive pay
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): February 27, 2020
(Exact name of registrant as specified in its charter)
(State or other | (Commission File | (I.R.S. Employer |
jurisdiction of | Number) | Identification No.) |
incorporation) | ||
(Zip Code) | ||
(Address of principal executive offices)
Registrant’s telephone number, including area code:
(212 ) 733-2323
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
Securities registered pursuant to Section 12(b) of the Act: | ||||
Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Election of Jennifer Damico as Principal Accounting Officer
On February 27, 2020, Loretta V. Cangialosi notified the Board that she will retire as Senior Vice President - Controller, effective March 1, 2020. Ms. Cangialosi had been designated the Company’s principal accounting officer. The Board elected Jennifer B. Damico, age 52, as Senior Vice President - Controller and the Company’s principal accounting officer, effective March 1, 2020. Ms. Damico joined Pfizer in 1992 and has held several positions with increasing responsibility in Audit and Finance. She has been the Company’s Senior Vice President - Corporate Audit and the Company’s lead internal auditor since 2014.
The Board also appointed Gordon Loh, Senior Vice President, Corporate Audit, reporting to the Audit Committee of the Board as well as the Company’s Chief Financial Officer, Frank D’Amelio, effective March 1, 2020. Mr. Loh has worked at Pfizer for 25 years and served in several positions of increasing responsibility, most recently as Vice President of Finance for Pfizer Global Supply.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
PFIZER INC. | ||
Dated: March 2, 2020 | By: | /s/ Margaret M. Madden |
Margaret M. Madden | ||
Senior Vice President and Corporate Secretary | ||
Chief Governance Counsel | ||